Affiliation:
1. Department of Cardiovascular Intervention, Nguyen Tri Phuong Hospital, Ho Chi Minh City, Vietnam; Faculty of Medicine, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam
2. Department of Cardiovascular Intervention, Nguyen Tri Phuong Hospital, Ho Chi Minh City, Vietnam
Abstract
Background: Left main (LM) coronary artery disease (CAD) is a severe condition that can lead to severe outcomes. Treatment options include medication, coronary artery bypass graft surgery (CABG) and percutaneous coronary intervention (PCI). Recent advancements in PCI techniques position it as a viable alternative to CABG for LM revascularisation. Methods: This prospective observational study evaluated outcomes after PCI for LM CAD, encompassing in-hospital and post-discharge mortality, in a single-centre registry in Vietnam. Results: Our research involved 59 patients who underwent PCI for LM lesions, with an average age of 66.7 ±1.5 years, who were divided into two groups based on presentation diagnosis – acute coronary syndrome or chronic coronary syndrome. After PCI, one individual was diagnosed with contrast-induced nephropathy and one with cardiac shock. There were two cases of in-hospital mortality in the acute coronary syndrome group and one in the chronic coronary syndrome group giving a rate of major adverse cardiac and cerebrovascular events (MACCE) of 5.1%. After a 12-month follow-up, the MACCE rate increased to 18.6%. Triple vessel coronary artery disease and troponin I elevation exhibited significant associations with adverse in-hospital outcomes (p<0.05). Conclusion: PCI for LM coronary artery disease is considered a safe treatment option, demonstrating relatively favourable in-hospital and mid-term outcomes. It presents a viable alternative for patients in need of revascularisation, particularly in cases where CABG is not the preferred choice. Clinical indicators, such as triple vessel coronary artery disease and elevated troponin I levels, may serve as predictors of adverse outcomes during hospitalisation.
Publisher
Radcliffe Media Media Ltd
Reference19 articles.
1. Mautner RK, Meeran MK, Kanade A, Phillips JH. Left main coronary artery disease. South Med J 1979;72:537–40. https://doi.org/10.1097/00007611-197905000-00011; PMID: 312531.
2. Collet C, Capodanno D, Onuma Y, et al. Left main coronary artery disease: pathophysiology, diagnosis, and treatment. Nat Rev Cardiol 2018;15:321–31. https://doi.org/10.1038/s41569-018-0001-4; PMID: 29599504.
3. Kolh P, Windecker S, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery. Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions. Eur J Cardiothorac Surg. 2014;46:517–92. https://doi.org/10.1093/ejcts/ezu366; PMID: 25173601.
4. Chieffo A, Tanaka A, Giustino G, et al. The DELTA 2 registry: A multicenter registry evaluating percutaneous coronary intervention with new-generation drug-eluting stents in patients with obstructive left main coronary artery disease. JACC Cardiovasc Interv 2017;10:2401–10. https://doi.org/10.1016/j.jcin.2017.08.050; PMID: 29217002.
5. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009;360:961–72. https://doi.org/10.1056/NEJMoa0804626; PMID: 19228612.